Medicine and Dentistry
Lung Transplantation
96%
Non Small Cell Lung Cancer
75%
Surgery
72%
Lung
61%
Lung Cancer
51%
Clinical Stage
40%
Overall Survival
35%
Esophageal Cancer
31%
Surgeon
27%
Esophagectomy
26%
Lobectomy
25%
Odds Ratio
24%
Pneumonectomy
22%
Malignant Neoplasm
22%
Thorax Surgery
20%
Neoplasm
19%
Hazard Ratio
18%
Lymph Node
16%
Transplantation
16%
Health Care Cost
15%
Radiation Therapy
13%
Stereotactic Body Radiation Therapy
13%
Diseases
13%
Computer Assisted Tomography
13%
Video-Assisted Thoracoscopic Surgery
12%
Primary Graft Dysfunction
12%
Cost-Effectiveness Analysis
12%
Comorbidity
11%
Chemoradiotherapy
10%
Allograft
10%
Adjuvant Chemotherapy
10%
Logistic Regression Analysis
9%
Lung Cancer Screening
8%
Organ Donor
8%
Clinical Trial
8%
Acute Graft Rejection
7%
Heart Transplantation
7%
Veterans Health
7%
Proportional Hazards Model
7%
Organ Transplantation
6%
COVID-19
6%
Donor Management
6%
Cancer Surgery
6%
Adjuvant Therapy
6%
Prevalence
6%
Retrospective Cohort Study
6%
Patient-Reported Outcome
6%
Thoracic Cancer
6%
Endobronchial Ultrasonography
6%
Hernioplasty
6%
Keyphrases
Lung Transplantation
100%
Non-small Cell Lung Cancer (NSCLC)
54%
Stage I Lung Cancer
37%
Confidence Interval
36%
Lung Cancer
33%
Esophageal Cancer
30%
Lung
29%
Overall Survival
27%
Resection
22%
Esophagectomy
22%
Clinical Stage I
21%
Early-stage Lung Cancer
20%
Transplantation
18%
National Cancer Database
18%
Primary Graft Dysfunction
17%
Odds Ratio
16%
Hazard Ratio
16%
Surgical Treatment
15%
Pathologic
15%
Surgical Resection
15%
Improved Survival
14%
Thoracic Surgery
13%
Lobectomy
13%
Donor Lung
13%
Adjuvant Chemotherapy
11%
Induction Therapy
11%
Stereotactic Body Radiation Therapy
11%
Surgeons
10%
Computed Tomography
10%
Video-assisted Thoracoscopic Surgery
9%
Surgical Outcomes
9%
Clinical Outcomes
9%
30-day Mortality
8%
Healthcare Facilities
8%
Size Matching
8%
Donor Care
8%
Society of Thoracic Surgeons
8%
Allocation Policy
8%
Lung Donor
8%
Pathological Stage
8%
Pulmonary Resection
8%
Cost-effectiveness Analysis
8%
Node-positive
8%
Post-esophagectomy
7%
VATS Lobectomy
7%
5-year Survival
7%
Tumor
7%
Clinical High Risk
7%
Lung Allocation
7%
Lung Resection
7%